Skip to main content

letter

. 1996 Jan 27;312(7025):252. doi: 10.1136/bmj.312.7025.252b

Increasing prescription of drugs for secondary prevention of myocardial infarction. Lipid lowering drugs should be considered too.

A Taylor, J P Reckless

PMCID: PMC2350032 PMID: 8563613

252

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Durrington P. N., Bhatnagar D. Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet. 1992 Feb 22;339(8791):488–488. doi: 10.1016/0140-6736(92)91089-q. [DOI] [PubMed] [Google Scholar]
Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. doi: 10.1136/bmj.308.6925.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
Smith J., Channer K. S. Increasing prescription of drugs for secondary prevention after myocardial infarction. BMJ. 1995 Oct 7;311(7010):917–918. doi: 10.1136/bmj.311.7010.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
Watts G. F., Lewis B., Brunt J. N., Lewis E. S., Coltart D. J., Smith L. D., Mann J. I., Swan A. V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992 Mar 7;339(8793):563–569. doi: 10.1016/0140-6736(92)90863-x. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES